SFM
KNSA icon

Sphera Funds Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Sphera Funds Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-450,283
Closed -$4.85M – 92
2023
Q1 		$4.85M Buy
450,283
+143,000
+47% +$1.88M 0.81% 44
2022
Q4 		$4.6M Buy
+307,283
New +$4.47M 0.99% 31
2020
Q4 		– Sell
-259,990
Closed -$3.98M – 123
2020
Q3 		$3.98M Buy
+259,990
New +$4.88M 0.39% 66

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Sphera Funds Management's KNSA Position: Q2 2023 in Review

Sphera Funds Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2023, closing a stake of 450,283 shares — an estimated $4.85M sold.

Sphera Funds Management first reported a position in KNSA in Q3 2020 and held it in 3 quarters. The position peaked at $4.85M in Q1 2023. 127 funds tracked by Wall St. Rank hold KNSA as of Q2 2023.

  • Sphera Funds Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Sphera Funds Management sold 450,283 Kiniksa Pharmaceuticals shares in Q2 2023, an estimated $4.85M.
  • Sphera Funds Management first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Sphera Funds Management's Kiniksa Pharmaceuticals position peaked at $4.85M in Q1 2023.
  • 127 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2023.

Based on Sphera Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.